Truist Securities Maintains Buy on Beta Bionics, Lowers Price Target to $25
Benzinga Newsdesk 9 months ago
NewsPrice TargetAnalyst Ratings
Truist Securities analyst Richard Newitter maintains Beta Bionics (NASDAQ:BBNX) with a Buy and lowers the price target from $37 to $25.
Truist Securities analyst Richard Newitter maintains Beta Bionics (NASDAQ:BBNX) with a Buy and lowers the price target from $37 to $25.